Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 5/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | MAP2 | P11137 | 5/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.32 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13504588 | 0.78 | GPR17 (0.41) | GPR17DGAT1EGLN1 | |
| SCHEMBL976253 | 0.71 | GPR17 (0.48) | GPR17DGAT1PDPK1 | |
| SCHEMBL31219036 | 0.70 | MAP2 (0.47) | MAP2PDPK1 | |
| SCHEMBL975904 | 0.68 | RXFP1 (0.50) | MAP2PDPK1 | |
| SCHEMBL13362737 | 0.67 | DGAT1 (0.58) | DGAT1PKN1PKN2MAP2K1HDAC1 | |
| SCHEMBL29062814 | 0.67 | GPR17 (0.47) | GPR17DGAT1MAP2 | |
| SCHEMBL1317647 | 0.66 | DGAT1 (0.55) | GPR17DGAT1MAP2K1HDAC1HDAC6 | |
| SCHEMBL17362716 | 0.65 | MAP2K1 (0.40) | DGAT1MAP2MAP2K1PDPK1 | |
| SCHEMBL23723698 | 0.64 | DGAT1 (0.48) | DGAT1MAP2K1HDAC1HDAC6 | |
| SCHEMBL58096 | 0.62 | HDAC1 (0.44) | DGAT1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664233-B2 | Substituted 5H-pyrimido[5,4-B]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664233-B2 | Substituted 5H-pyrimido[5,4-B]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664233-B2 | Substituted 5H-pyrimido[5,4-B]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| EP-2104675-B1 | SUBSTITUTED 5H-PYRIMIDOL[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | MEDICINES CO LEIPZIG GMBH (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20110021511-A1 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021511-A1 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021511-A1 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2008077631-A1 | SUBSTITUTED 5H-PYRIMIDOL[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021511-A1 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | BCL6, BCL3, BCL6B | GPR17 884/4885DGAT1 4619/4885MAP2 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.